Drug Companies Are Looking at Multiple Ways to Reduce their 340B Exposure

Some drug manufacturers have grabbed headlines and precipitated lawsuits for ending 340B pricing on drugs dispensed by contract pharmacies. But behind the scenes, the companies also are investing in other ways to reduce their exposure to 340B program sales, which a major industry consulting firm says have been growing on average by 25 percent per year since 2014.